

IN THE CLAIMS

1. (currently amended) A composition for treating squamous cell carcinoma (SCC) comprising ~~an~~ a monoclonal antibody against a migration facilitating protein (MFP) an epitope in the human laminin 5 alpha 3 G4-5 domain, which antibody specifically binds an epitope in the human laminin 5 alpha 3 G4-5 domain lying between amino acid 1399 and amino acid 1713 of SEQ ID NO:21, and a pharmaceutically acceptable carrier.

2. (currently amended) A composition for treating squamous cell carcinoma (SCC) comprising a monoclonal antibody against an epitope in the human laminin 5 alpha 3 G4-5 domain ~~A composition according to Claim 1~~, wherein said antibody binds to an epitope in the laminin 5 alpha 3 G4 domain lying between amino acid 1375 and amino acid 1390 of SEQ ID NO:21 and a pharmaceutically acceptable carrier.

3. (currently amended) A composition according to ~~Claim 2~~ Claim 1, wherein said antibody does not bind to an epitope for a BMP-1 cleavage site within said laminin 5 alpha 3 G4 domain.

4. (currently amended) A composition for treating squamous cell carcinoma (SCC) comprising a monoclonal antibody against an epitope in the human laminin 5 alpha 3 G4-5 domain ~~A composition according to Claim 1~~, wherein said antibody binds to an epitope in laminin 5 alpha 3 G4 domain lying between amino acid 1358 and amino acid 1366 of SEQ ID NO:21 and a pharmaceutically acceptable carrier.

5-6. (canceled)

7. (original) A composition according to Claim 1, wherein said SCC is selected from the group consisting of skin cancer, lung cancer, head cancer, gastric cancer, colorectal, throat cancer, cancer of the urinary tract, cancer of the reproductive tract, esophageal cancer, and bronchiogenic carcinoma.

8-43. (canceled)